Therefore, our data reveals an unknown positive feedback loop of FBXL6-HSP90AA1-c-MYC axis, and its abnormal regulation may contribute to the occurrence of HCC, and suggests that agents targeting FBXL6 will be beneficial to inhibit HCC. This evidence concerns the gene FBXL6 and hepatocellular carcinoma.